Urovant Sciences announced Sef Kurstjens, M.D., PhD., has been appointed Executive Vice President and Chief Medical Officer (CMO). Concurrent with this appointment, Dr. Kurstjens will step down as a member of Urovant's Board of Directors, a position he has held since July 2018, to pursue the full-time CMO role. Dr. Kurstjens will assume his new role as CMO effective April 1, 2022.

He will report to Mr. Robinson and will serve as a member of the company's executive leadership team. Throughout his career Dr. Kurstjens has held positions of increasing responsibility. Prior to Urovant, he served as the CEO for Bright Peak Therapeutics, CMO for Astellas Pharma Inc., President and CEO for Agensys Inc., CMO for Allergan Inc., Senior Vice President of R&D at Astellas Pharma Inc., and Vice President of Clinical Development at Pfizer.